EPO and metabolic dysfunction-associated steatotic liver disease: In a mouse model of non-alcoholic fatty liver disease, EPO administration reduced body weight, reversed glucose intolerance and insulin resistance, reduced lipid accumulation in the liver and WAT, suppressed lipid synthesis genes in the liver, and increased lipolysis proteins in adipose tissue [64].